• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

雾化重组活化凝血因子VII（rFVIIa）不能减轻爆震性肺损伤的出血效应。

Nebulised recombinant activated factor VII (rFVIIa) does not attenuate the haemorrhagic effects of blast lung injury.

作者信息

Smith Jason E, Watts S, Spear A M, Wilson C, Kirkman E

机构信息

CBR Division, Dstl Porton Down, Salisbury, UK.

Academic Department of Military Emergency Medicine, Royal Centre for Defence Medicine, Birmingham, UK.

出版信息

J R Army Med Corps. 2019 Feb;165(1):51-56. doi: 10.1136/jramc-2018-001029. Epub 2018 Nov 12.

DOI:10.1136/jramc-2018-001029
PMID:30420554
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6581091/
Abstract

INTRODUCTION

Primary blast lung injury causes intrapulmonary haemorrhage. A number of case reports have suggested the efficacy of recombinant activated factor VII (rFVIIa) in the treatment of diffuse alveolar haemorrhage from a range of medical causes, but its efficacy in blast lung is unknown. The aim of this study was to investigate whether nebulised rFVIIa attenuates the haemorrhagic effects of blast lung injury in an animal model.

METHODS

Terminally anaesthetised rabbits subjected to blast lung injury were randomised to receive either rFVIIa or placebo via a nebuliser. The primary outcome was the level of blood iron-transferrin complex, a marker of the extent of blast lung injury, analysed using low temperature electron paramagnetic resonance spectroscopy.

RESULTS

Blast exposure led to a significant fall in iron-bound transferrin in both groups of animals (p<0.001), which remained depressed during the study. There were no significant differences in iron-transferrin between the rFVIIa and placebo treatment groups over the duration of the study (p=0.081), and there was no trend towards elevated iron-transferrin in the rFVIIa-treated group once drug treatment had started. There was suggestive evidence of systemic absorption of rFVIIa given via the inhaled route.

CONCLUSION

A single dose of nebulised rFVIIa did not attenuate pulmonary haemorrhage in a rabbit model of blast lung injury. As there was some evidence of systemic absorption, the inhaled route does not avoid the concern about potential thromboembolic complications from administration of rFVIIa.

摘要

引言

原发性爆震性肺损伤可导致肺内出血。多项病例报告提示重组活化因子VII（rFVIIa）在治疗多种医学原因引起的弥漫性肺泡出血方面具有疗效，但其在爆震性肺损伤中的疗效尚不清楚。本研究的目的是调查雾化吸入rFVIIa是否能减轻动物模型中爆震性肺损伤的出血效应。

方法

对接受爆震性肺损伤的终末期麻醉兔进行随机分组，通过雾化器分别给予rFVIIa或安慰剂。主要结局是血铁转铁蛋白复合物水平，这是爆震性肺损伤程度的一个指标，采用低温电子顺磁共振波谱分析。

结果

两组动物爆震暴露后铁结合转铁蛋白均显著下降（p<0.001），且在研究期间一直处于较低水平。在研究期间，rFVIIa治疗组和安慰剂治疗组的铁转铁蛋白水平无显著差异（p=0.081），且rFVIIa治疗组在开始药物治疗后铁转铁蛋白也没有升高的趋势。有证据提示经吸入途径给予的rFVIIa存在全身吸收。

结论

在兔爆震性肺损伤模型中，单剂量雾化吸入rFVIIa并不能减轻肺出血。由于有证据表明存在全身吸收，吸入途径并不能消除对rFVIIa给药潜在血栓栓塞并发症的担忧。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb4a/6581091/c83ea26239cf/jramc-2018-001029f09.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb4a/6581091/b11a4a084c19/jramc-2018-001029f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb4a/6581091/967f13c9fbef/jramc-2018-001029f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb4a/6581091/9109d088c9ea/jramc-2018-001029f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb4a/6581091/518cf27ba5f8/jramc-2018-001029f04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb4a/6581091/ef372a4a559f/jramc-2018-001029f05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb4a/6581091/3d8229938a4f/jramc-2018-001029f06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb4a/6581091/776485713453/jramc-2018-001029f07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb4a/6581091/bd3fa9d21740/jramc-2018-001029f08.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb4a/6581091/c83ea26239cf/jramc-2018-001029f09.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb4a/6581091/b11a4a084c19/jramc-2018-001029f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb4a/6581091/967f13c9fbef/jramc-2018-001029f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb4a/6581091/9109d088c9ea/jramc-2018-001029f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb4a/6581091/518cf27ba5f8/jramc-2018-001029f04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb4a/6581091/ef372a4a559f/jramc-2018-001029f05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb4a/6581091/3d8229938a4f/jramc-2018-001029f06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb4a/6581091/776485713453/jramc-2018-001029f07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb4a/6581091/bd3fa9d21740/jramc-2018-001029f08.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb4a/6581091/c83ea26239cf/jramc-2018-001029f09.jpg

相似文献

1
Nebulised recombinant activated factor VII (rFVIIa) does not attenuate the haemorrhagic effects of blast lung injury.雾化重组活化凝血因子VII（rFVIIa）不能减轻爆震性肺损伤的出血效应。
J R Army Med Corps. 2019 Feb;165(1):51-56. doi: 10.1136/jramc-2018-001029. Epub 2018 Nov 12.
2
Evaluation of recombinant factor VIIa, tranexamic acid and desmopressin to reduce prasugrel-related bleeding: A randomised, placebo-controlled study in a rabbit model.评价重组因子 VIIa、氨甲环酸和去氨加压素减少普拉格雷相关出血的效果：在兔模型中进行的一项随机、安慰剂对照研究。
Eur J Anaesthesiol. 2018 Mar;35(3):208-214. doi: 10.1097/EJA.0000000000000775.
3
Recombinant activated factor VII attenuates major arterial bleeding in noncoagulopathic rabbits.重组活化因子 VII 可减轻非凝血性兔的主要动脉出血。
Eur J Anaesthesiol. 2011 Jan;28(1):51-6. doi: 10.1097/EJA.0b013e32833cf067.
4
Recombinant activated factor VII does not reduce bleeding in rabbits treated with aspirin and clopidogrel.重组活化因子 VII 并未减少阿司匹林和氯吡格雷治疗的兔子的出血。
Thromb Haemost. 2010 Oct;104(4):823-30. doi: 10.1160/TH10-01-0039. Epub 2010 Jul 20.
5
Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries.静脉注射重组活化凝血因子VII用于控制伴有V级肝损伤的低温凝血障碍猪的出血。
J Trauma. 2001 Apr;50(4):721-9. doi: 10.1097/00005373-200104000-00021.
6
Recombinant activated factor VII increases survival time in a model of incompressible arterial hemorrhage in the anesthetized pig.重组活化因子VII可延长麻醉猪不可压缩性动脉出血模型的存活时间。
J Trauma. 2007 Apr;62(4):868-79. doi: 10.1097/ta.0b013e318034204b.
7
Recombinant activated factor VII efficacy and safety in a model of bleeding and thrombosis in hypothermic rabbits: a blind study.重组活化因子VII在低温兔出血和血栓形成模型中的疗效与安全性：一项盲法研究。
J Thromb Haemost. 2007 Feb;5(2):244-9. doi: 10.1111/j.1538-7836.2007.02320.x. Epub 2006 Nov 27.
8
The use of recombinant activated factor VII (rFVIIa) in the management of patients with major haemorrhage in military hospitals over the last 5 years.重组活化因子 VII（rFVIIa）在过去 5 年中在军队医院中用于治疗大出血患者的应用。
Emerg Med J. 2013 Apr;30(4):316-9. doi: 10.1136/emermed-2012-201334. Epub 2012 May 19.
9
Low-dose recombinant factor VIIa for massive bleeding: a single centre observational cohort study with 73 patients.低剂量重组 VII 因子治疗大出血：一项 73 例患者的单中心观察性队列研究。
Swiss Med Wkly. 2011 Jul 7;141:w13213. doi: 10.4414/smw.2011.13213. eCollection 2011.
10
Recombinant factor VIIa as last-resort treatment of desperate haemorrhage.重组 VII 因子作为治疗绝望性大出血的最后手段。
Acta Anaesthesiol Scand. 2012 May;56(5):636-44. doi: 10.1111/j.1399-6576.2012.02688.x.

引用本文的文献

1
Crosstalk between Inflammation and Hemorrhage/Coagulation Disorders in Primary Blast Lung Injury.原发冲击性肺损伤中炎症与出血/凝血障碍的相互作用。
Biomolecules. 2023 Feb 10;13(2):351. doi: 10.3390/biom13020351.
2
DDAH1 Promotes Lung Endothelial Barrier Repair by Decreasing Leukocyte Transendothelial Migration and Oxidative Stress in Explosion-Induced Lung Injury.DDHA1 通过减少白细胞跨内皮迁移和氧化应激促进爆炸致肺损伤的肺内皮屏障修复。
Oxid Med Cell Longev. 2022 May 17;2022:8407635. doi: 10.1155/2022/8407635. eCollection 2022.
3
Life-Threatening Pulmonary Hemorrhage Responds to Recombinant Factor VIIa: A Case Series in South Florida Hospitals.

本文引用的文献

1
Trauma Hemostasis and Oxygenation Research Network position paper on the role of hypotensive resuscitation as part of remote damage control resuscitation.创伤止血与氧合研究网络关于低血压复苏作为远程损伤控制性复苏的一部分的作用的立场文件。
J Trauma Acute Care Surg. 2018 Jun;84(6S Suppl 1):S3-S13. doi: 10.1097/TA.0000000000001856.
2
Safety update on the use of recombinant activated factor VII in approved indications.重组活化凝血因子 VII 在获批适应症中使用的安全性更新
Blood Rev. 2015 Jun;29 Suppl 1:S34-41. doi: 10.1016/S0268-960X(15)30006-0.
3
The use of recombinant activated factor VII (rFVIIa) in the management of patients with major haemorrhage in military hospitals over the last 5 years.
危及生命的肺出血对重组凝血因子VIIa有反应：南佛罗里达医院的病例系列
Cureus. 2019 Nov 19;11(11):e6202. doi: 10.7759/cureus.6202.
重组活化因子 VII（rFVIIa）在过去 5 年中在军队医院中用于治疗大出血患者的应用。
Emerg Med J. 2013 Apr;30(4):316-9. doi: 10.1136/emermed-2012-201334. Epub 2012 May 19.
4
Tissue factor and factor VIIa cross-species compatibility.组织因子和因子 VIIa 的种间兼容性。
Front Biosci (Landmark Ed). 2011 Jun 1;16(9):3196-215. doi: 10.2741/3906.
5
Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records.美国医院重组因子 VIIa 的超适应证使用：医院记录分析。
Ann Intern Med. 2011 Apr 19;154(8):516-22. doi: 10.7326/0003-4819-154-8-201104190-00002.
6
[Efficacy of recombinant activated factor VII in diffuse alveolar haemorrhage].重组活化凝血因子VII治疗弥漫性肺泡出血的疗效
Rev Mal Respir. 2011 Jan;28(1):106-11. doi: 10.1016/j.rmr.2010.07.007. Epub 2011 Jan 11.
7
The epidemiology of blast lung injury during recent military conflicts: a retrospective database review of cases presenting to deployed military hospitals, 2003-2009.爆炸肺损伤在近期军事冲突中的流行病学：2003-2009 年部署军事医院收治病例的回顾性数据库研究。
Philos Trans R Soc Lond B Biol Sci. 2011 Jan 27;366(1562):291-4. doi: 10.1098/rstb.2010.0251.
8
Characterization of the response to primary blast injury.原发性爆炸伤反应的特征。
Philos Trans R Soc Lond B Biol Sci. 2011 Jan 27;366(1562):286-90. doi: 10.1098/rstb.2010.0249.
9
Prolonged permissive hypotensive resuscitation is associated with poor outcome in primary blast injury with controlled hemorrhage.在控制出血的原发性爆炸伤中，长时间的允许性低血压复苏与不良预后相关。
Ann Surg. 2010 Jun;251(6):1131-9. doi: 10.1097/SLA.0b013e3181e00fcb.
10
Attenuation of pulmonary inflammation after exposure to blast overpressure by N-acetylcysteine amide.N-乙酰半胱氨酸酰胺减轻暴露于爆炸超压后的肺部炎症。
Shock. 2009 Sep;32(3):325-31. doi: 10.1097/SHK.0b013e31819c38f1.